Literature DB >> 28418163

Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease.

Ulrike Lueken1,2, Ricarda Evens2, Monika Balzer-Geldsetzer3, Simon Baudrexel4, Richard Dodel3, Susanne Gräber-Sultan5, Rüdiger Hilker-Roggendorf4, Elke Kalbe6, Oliver Kaut7, Brit Mollenhauer8, Kathrin Reetz9,10,11, Eva Schäffer5, Nele Schmidt12, Jörg B Schulz9,10,11, Annika Spottke7, Karsten Witt12, Katharina Linse13, Alexander Storch13,14, Oliver Riedel2,15.   

Abstract

Parkinson's disease (PD) frequently entails non-motor symptoms, worsening the course of the disease. Apathy is one of the core neuropsychiatric symptoms that has been investigated in recent years; research is however hampered by the limited availability of well-evaluated apathy scales for these patients. We evaluated the psychometric properties of the Apathy Evaluation Scale (AES) in a sample of PD patients. Psychometric properties, convergent and discriminant validity and sensitivity/specificity were evaluated in patients with (n = 582) or without dementia/depression (n = 339). Internal consistency was high in the entire sample as well as in patients without dementia/depression. Correlations were moderate for convergent validity (UPDRS I item 4: motivation). While apathy could be differentiated from cognitive decline, it was related to depression (Geriatric Depression Scale, GDS-15). The overall classification accuracy based on the UPDRS I item 4 was comparable for AES and GDS scores. The AES exhibits good psychometric properties in PD patients with and without dementia and/or depression. Commonly used screenings on the presence of apathy had low detection rates compared to the AES and reflected both apathetic and depressive symptoms. Psychometric evaluation of available instruments will support further research on the clinical relevance of apathy for disease progression and treatment approaches in PD patients.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Parkinson's disease; apathy; depression; psychometrics; validity

Mesh:

Year:  2017        PMID: 28418163      PMCID: PMC6877280          DOI: 10.1002/mpr.1564

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  37 in total

1.  Parkinson's disease and dementia: a longitudinal study (DEMPARK).

Authors:  Monika Balzer-Geldsetzer; Ana Sofia Ferreira Braga da Costa; Martin Kronenbürger; Jörg B Schulz; Sandra Röske; Annika Spottke; Ullrich Wüllner; Thomas Klockgether; Alexander Storch; Christine Schneider; Oliver Riedel; Hans-Ulrich Wittchen; Carola Seifried; Rüdiger Hilker; Nele Schmidt; Karsten Witt; Günther Deuschl; Brit Mollenhauer; Claudia Trenkwalder; Inga Liepelt-Scarfone; Susanne Gräber-Sultan; Daniela Berg; Thomas Gasser; Elke Kalbe; Maren Bodden; Wolfgang H Oertel; Richard Dodel
Journal:  Neuroepidemiology       Date:  2011-11-04       Impact factor: 3.282

2.  Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease.

Authors:  Kenn Freddy Pedersen; Jan Petter Larsen; Dag Aarsland
Journal:  Parkinsonism Relat Disord       Date:  2007-09-21       Impact factor: 4.891

3.  Reliability and validity of the Apathy Evaluation Scale.

Authors:  R S Marin; R C Biedrzycki; S Firinciogullari
Journal:  Psychiatry Res       Date:  1991-08       Impact factor: 3.222

4.  The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.

Authors:  London C Butterfield; Cynthia R Cimino; Lynn E Oelke; Robert A Hauser; Juan Sanchez-Ramos
Journal:  Neuropsychology       Date:  2010-11       Impact factor: 3.295

5.  Diagnostic criteria for apathy in clinical practice.

Authors:  E Mulin; E Leone; K Dujardin; M Delliaux; A Leentjens; F Nobili; B Dessi; O Tible; L Agüera-Ortiz; R S Osorio; J Yessavage; D Dachevsky; F R J Verhey; Alfonso J Cruz Jentoft; O Blanc; P M Llorca; P H Robert
Journal:  Int J Geriatr Psychiatry       Date:  2011-02       Impact factor: 3.485

6.  [Psychometric properties of a German version of the Apathy Evaluation Scale].

Authors:  U Lueken; U Seidl; M Schwarz; L Völker; D Naumann; K Mattes; J Schröder; E Schweiger
Journal:  Fortschr Neurol Psychiatr       Date:  2006-12       Impact factor: 0.752

7.  Apathy may herald cognitive decline and dementia in Parkinson's disease.

Authors:  Kathy Dujardin; Pascal Sockeel; Marie Delliaux; Alain Destée; Luc Defebvre
Journal:  Mov Disord       Date:  2009-12-15       Impact factor: 10.338

8.  How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale?

Authors:  Lindsey Kirsch-Darrow; Laura B Zahodne; Chris Hass; Ania Mikos; Michael S Okun; Hubert H Fernandez; Dawn Bowers
Journal:  Mov Disord       Date:  2009-04-15       Impact factor: 10.338

Review 9.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  1 in total

1.  Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease.

Authors:  Ulrike Lueken; Ricarda Evens; Monika Balzer-Geldsetzer; Simon Baudrexel; Richard Dodel; Susanne Gräber-Sultan; Rüdiger Hilker-Roggendorf; Elke Kalbe; Oliver Kaut; Brit Mollenhauer; Kathrin Reetz; Eva Schäffer; Nele Schmidt; Jörg B Schulz; Annika Spottke; Karsten Witt; Katharina Linse; Alexander Storch; Oliver Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-04-18       Impact factor: 4.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.